Clinical Trials | December 21, 2025
Soligenix publishes promising Phase 2a data for SGX945 in Behcet's Disease
SGX945 delivered beneficial effects in 7 of 8 patients suffering from painful oral ulcers
SGX945 delivered beneficial effects in 7 of 8 patients suffering from painful oral ulcers
Developed in partnership with the Johns Hopkins Applied Physics Laboratory (APL), the module is built around a multi-segment RT-PCR method with integrated indexing
The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made COVID-19 vaccines to the UK population
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Malaria is a life-threatening parasitic infection that is spread by the bites of mosquitoes carrying the Plasmodium parasite
Company to open new headquarters in 2024
Steve joins Sai Life Sciences from GlaxoSmithKline (GSK) where he was a department head and member of the global chemical development leadership team.
Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
Up to $30m funding will be provided to advance an innovative vaccine technology that could protect against current and future SARS-CoV-2 variants and other SARS-like Betacoronaviruses.
CEPI will expand its partnership with icddr,b in Bangladesh, providing near to the additional US $ 1 million in funding to advance understanding of the Nipah virus
Subscribe To Our Newsletter & Stay Updated
